Roivant Sciences Ltd at Jefferies London Healthcare Conference Transcript
I'm very pleased to have Roivant here and CEO, Matt Gline. So I mean, obviously, there has been -- there have been a lot of developments this year to the positive. The company has clearly been executing across the pipeline, including deals that have been done.
Questions & Answers
So maybe to level set everybody here in the room. Just remind us of all of the different developments and updates that you guys had this year? And sort of how should we think about the outlook through the end of the year?
Yes, perfect. It's actually a nice bookend because I just think back to literally a year ago at this conference. And a year ago at this conference, the biggest things in our world is we had recently announced preclinical data for our next-generation anti-FcRn antibody. And what I knew, but nobody else did is that we were on the cusp of acquiring an anti-TL1A antibody.
We have not yet generated any atopic dermatitis. We
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
